Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie, Acelity, AstraZeneca, Celgene Corporation, Daiichi Sankyo, Inc., Eisai, Genentech, Genomic Health, Inc., Lilly, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pacira Pharmaceuticals, Inc., Pfizer, Puma Biotechnology, and Syndax Pharmaceuticals, Inc.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

35th Annual Miami Breast Cancer Conferences® Clinical Case Vignette Series™


Release Date: May 31, 2018
Expiration Date: May 31, 2019
Media: Internet - based

 

Activity Overview

Strategies for achieving the best possible outcomes for patients with breast cancer are prone to rapid change because of the pace at which advances in patient care across the cancer care continuum emerge. The Annual Miami Breast Cancer Conference® brings together breast cancer specialists to highlight the state-of-the-art multidisciplinary patient care. This year’s conference was no exception, with an agenda that featured clinical updates in local, regional, and systemic therapies; timely practice management and policy concerns; exploration of clinical controversies; patient-centered care (eg, patient‒clinician communication, care of the older patient, psychosocial concerns, pain); and much more.

This online CME/CE-certified educational activity based on content presented at the Miami Breast Cancer Conference® consists of a series of interviews with Sara Hurvitz, MD, Debu Tripathy, MD, and Pat Whitworth, MD, during which they discuss their approaches toward clinical cases and other topics important to the practicing community clinician. Specifically, these renowned experts review current and emerging evidence on systemic therapy for various breast cancer subtypes, as well as a thought-provoking exploration of the impact of current criteria for breast cancer genetic testing.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie, Acelity, AstraZeneca, Celgene Corporation, Daiichi Sankyo, Inc., Eisai, Genentech, Genomic Health, Inc., Lilly, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pacira Pharmaceuticals, Inc., Pfizer, Puma Biotechnology, and Syndax Pharmaceuticals, Inc.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

 

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This educational program is directed toward medical, surgical, and radiation oncologists and nurses interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, physician assistants, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Summarize clinical trial evidence that allows for the personalization of care in the management of early and advanced forms of breast cancer
  • Select multimodal, evidence-based treatment approaches to optimize outcomes for patients with nonmetastatic breast cancer
  • Outline multidisciplinary methods to identify and manage treatment-related toxicities for patients with breast cancer
  • Appraise the influence on evolving treatment paradigms of recent clinical trial data pertaining to novel breast cancer treatment strategies

Faculty, Staff, and Planners' Disclosures

Faculty

Debu Tripathy, MD
Professor and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
 

Disclosure: Grant/Research Support: Novartis; Consultant: Nektar, Novartis, Pfizer

Sara A. Hurvitz, MD
Associate Professor of Medicine, Division of Hematology/Oncology
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica–UCLA Outpatient Hematology/Oncology Practice
David Geffen School of Medicine at UCLA
Santa Monica, CA

Disclosure: Grant/Research Support: Amgen, Bayer, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Pfizer, Roche, BioMarin, Merrimack, OBI Pharma, Puma Biotechnology, Dignitana, Medivation, Lilly, Novartis; Other: Travel ‒ Lilly, Novartis, OBI Pharma

Patrick W. Whitworth, MD
Director
Nashville Breast Center
Nashville, TN
 
 

Disclosure: Grant/Research Support: Targeted Medical Education, Inc.; Stock/Shareholder: Targeted Medical Education, Advantage Consulting and Education, Advantage Clinical Research, Nashville Breast Center

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

PER Pulse Recap™

PER Pulse Recap (1 of 3)

35th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series is a series of short video interviews with faculty from the live 35th Annual Miami Breast Cancer Conference® who address a variety of questions via discussions of clinical vignettes that were presented at the conference. The online activity features discussion on the following:
  • PARP Inhibition for Breast Cancer, Debu Tripathy, MD
  • Immunotherapy in Breast Cancer, Debu Tripathy, MD
  • Very Early HER2+ Breast Cancer, Sara Hurvitz, MD
  • Breast Cancer Susceptibility Gene Testing, Pat Whitworth, MD
Throughout the activity, these physicians answer questions about their decisions for managing cases and offer perspectives and guidance on issues important to community-based physicians.
This first of 3 PER Pulse Recaps summarizing the online program focuses on interviews with Dr. Tripathy, during which he discussed:
  • His approach toward initial therapy for a 62-year-old woman with a BRCA1 mutation who has bone and liver metastases after adjuvant systemic therapy for triple-negative breast cancer
  • Key data that led to the January 2018 approval of olaparib for HER2-negative germline BRCA1/2-mutated breast cancer
  • Approaches for tailoring therapy for patients with estrogen receptor–positive disease and those without a BRCA mutation
  • Best practices for preventing and treating adverse effects from olaparib
  • The evolving landscape of PARP inhibitors, including investigational agents on the horizon, the clinical significance of PARP trapping, trials analyzing combination therapies, and the latest clinical data on biomarkers for patient selection

PER Pulse Recap (2 of 3)

This second of 3 PER Pulse Recaps summarizing the online program focuses on interviews with Dr. Tripathy, during which he discussed:
  • His approach toward shared decision making with a female patient with recurrent metastatic triple-negative breast cancer who wishes to enroll in a clinical trial of an immune checkpoint inhibitor
  • The current state of immunotherapy in breast cancer, including recent data on single-agent checkpoint inhibitors for metastatic disease and other highly anticipated trial results
  • His perspective on what types of patients will benefit most from clinical trials in immunotherapy
  • The use of novel trial designs to progress research on the use of immunotherapy for breast cancer

PER Pulse Recap (3 of 3)

This third of 3 PER Pulse Recaps summarizing the online program focuses on interviews with Dr. Hurvitz, during which she discussed:
  • Her approach toward presurgical BRCA testing for a 40-year-old woman diagnosed with high-grade ductal carcinoma in situ whose mother was treated for stage I breast cancer at age 50
  • Patient selection for adjuvant systemic therapy and the currently available treatment options based on clinical trial data
  • Her treatment decisions for a 70-year-old healthy woman with grade 2 invasive ductal carcinoma, ER 80% 2+, PR negative, HER2 3+ by immunohistochemistry, and fluorescence in situ hybridization positive
Important factors to consider in early HER2-positive breast cancer, including the use of neoadjuvant therapy, risk of recurrence, and patient characteristics to guide treatment decision making






Become a Member

Forgot Password?
Filter By